Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
©2021 The Authors; Published by the American Association for Cancer Research..
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for relapse of 4.5 [95% confidence interval (CI), 2.03-9.97; P < 0.001]. Multivariate analysis at day 28 showed independent associations of BMNGS-MRD >0 (HR = 4.87; 95% CI, 2.18-10.8; P < 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44-7.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased to 12 (95% CI, 2.87-50; P < 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27; 95% CI, 0.33-4.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19- (23/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion. SIGNIFICANCE: Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers may benefit from HCT or investigational cell therapies.See related commentary by Ghorashian and Bartram, p. 2.This article is highlighted in the In This Issue feature, p. 1.
Errataetall: |
CommentIn: Blood Cancer Discov. 2022 Jan;3(1):2-4. - PMID 35019857 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
---|---|
Enthalten in: |
Blood cancer discovery - 3(2022), 1 vom: 12. Jan., Seite 66-81 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pulsipher, Michael A [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antigens, CD19 |
---|
Anmerkungen: |
Date Completed 05.05.2022 Date Revised 15.02.2023 published: Print-Electronic CommentIn: Blood Cancer Discov. 2022 Jan;3(1):2-4. - PMID 35019857 Citation Status MEDLINE |
---|
doi: |
10.1158/2643-3230.BCD-21-0095 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335548318 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335548318 | ||
003 | DE-627 | ||
005 | 20231225230111.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1158/2643-3230.BCD-21-0095 |2 doi | |
028 | 5 | 2 | |a pubmed24n1118.xml |
035 | |a (DE-627)NLM335548318 | ||
035 | |a (NLM)35019853 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pulsipher, Michael A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.05.2022 | ||
500 | |a Date Revised 15.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a CommentIn: Blood Cancer Discov. 2022 Jan;3(1):2-4. - PMID 35019857 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a ©2021 The Authors; Published by the American Association for Cancer Research. | ||
520 | |a We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for relapse of 4.5 [95% confidence interval (CI), 2.03-9.97; P < 0.001]. Multivariate analysis at day 28 showed independent associations of BMNGS-MRD >0 (HR = 4.87; 95% CI, 2.18-10.8; P < 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44-7.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased to 12 (95% CI, 2.87-50; P < 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27; 95% CI, 0.33-4.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19- (23/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion. SIGNIFICANCE: Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers may benefit from HCT or investigational cell therapies.See related commentary by Ghorashian and Bartram, p. 2.This article is highlighted in the In This Issue feature, p. 1 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antigens, CD19 |2 NLM | |
650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
650 | 7 | |a tisagenlecleucel |2 NLM | |
650 | 7 | |a Q6C9WHR03O |2 NLM | |
700 | 1 | |a Han, Xia |e verfasserin |4 aut | |
700 | 1 | |a Maude, Shannon L |e verfasserin |4 aut | |
700 | 1 | |a Laetsch, Theodore W |e verfasserin |4 aut | |
700 | 1 | |a Qayed, Muna |e verfasserin |4 aut | |
700 | 1 | |a Rives, Susana |e verfasserin |4 aut | |
700 | 1 | |a Boyer, Michael W |e verfasserin |4 aut | |
700 | 1 | |a Hiramatsu, Hidefumi |e verfasserin |4 aut | |
700 | 1 | |a Yanik, Gregory A |e verfasserin |4 aut | |
700 | 1 | |a Driscoll, Tim |e verfasserin |4 aut | |
700 | 1 | |a Myers, G Doug |e verfasserin |4 aut | |
700 | 1 | |a Bader, Peter |e verfasserin |4 aut | |
700 | 1 | |a Baruchel, Andre |e verfasserin |4 aut | |
700 | 1 | |a Buechner, Jochen |e verfasserin |4 aut | |
700 | 1 | |a Stefanski, Heather E |e verfasserin |4 aut | |
700 | 1 | |a Kalfoglou, Creton |e verfasserin |4 aut | |
700 | 1 | |a Nguyen, Kevin |e verfasserin |4 aut | |
700 | 1 | |a Waldron, Edward R |e verfasserin |4 aut | |
700 | 1 | |a Thudium Mueller, Karen |e verfasserin |4 aut | |
700 | 1 | |a Maier, Harald J |e verfasserin |4 aut | |
700 | 1 | |a Kari, Gabor |e verfasserin |4 aut | |
700 | 1 | |a Grupp, Stephan A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood cancer discovery |d 2020 |g 3(2022), 1 vom: 12. Jan., Seite 66-81 |w (DE-627)NLM31368555X |x 2643-3249 |7 nnns |
773 | 1 | 8 | |g volume:3 |g year:2022 |g number:1 |g day:12 |g month:01 |g pages:66-81 |
856 | 4 | 0 | |u http://dx.doi.org/10.1158/2643-3230.BCD-21-0095 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 3 |j 2022 |e 1 |b 12 |c 01 |h 66-81 |